NCT00844883已完成2 期
Phase II Trial of Sorafenib Combined With Doxorubicin Eluting Bead-Transarterial Chemoembolization (LC Bead-TACE) for Patients With Hepatocellular Carcinoma
适应症
干预措施
相关药物
试验速览
- 阶段
- 2 期
- 状态
- 已完成
- 入组人数
- 50
- 试验地点
- 1
- 主要终点
- Safety Will be Assessed by Grading Toxicities Reported at Intervals Throughout the Study. Higher Grade Toxicities Will be Assessed for Their Degree of Relatedness to the Study Treatment.
研究概览
简要总结
This study will combine two therapies to treat patients with unresectable hepatocellular carcinoma; sorafenib, and drug eluting beads delivered intra-arterially. The purpose of the study is to establish the safety and the effectiveness of the combination therapy. The investigators hypothesize that the combination of the two therapies will not result in greater toxicities to patients than that expected for either therapy given alone.
研究设计
- 研究类型
- Interventional
- 分配方式
- Na
- 干预模型
- Single Group
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Unresectable hepatocellular carcinoma (HCC) patients with liver-predominant disease as described in section 5.1, or patients with hepatocellular carcinoma who refuse surgery. No more than 30% of the cohort should have macrovascular invasion and/or asymptomatic extrahepatic disease. Multifocal HCC is acceptable, no diffuse HCC.
- •Age > 18 years old
- •Eastern Cooperative Oncology Group (ECOG) performance status of 0-1
- •Childs class of A or B (up to 7) (see Table 5.0)
- •Adequate end-organ function as manifested by:
- •Absolute neutrophil count of > 1500/mm3 and platelets > 50,000/mm3
- •Creatinine ≤ 2.0
- •Aspartate aminotransferase (AST), Alanine aminotransferase (ALT) < 5 x upper limit of normal (ULN)
- •Total bilirubin of ≤ 3
- •Albumin > 2.0
- •International normalized ratio (INR) < 2.0
- •Leukocyte count >3000 cells/mm3
- •Amylase and lipase ≤ 1.5 the upper limit of normal
- •Patients who have received previous hepatic surgery , radiofrequency ablation (RFA), percutaneous ethanol injection (PEI), or cryoablation are eligible if target lesion(s) have not been treated and local therapy completed > 6 weeks prior to entry.
- •Left ventricular ejection fraction ≥ 45%
- •Patients with asymptomatic HIV infection are not eligible
- •Willingness of male and female subjects, who are not surgically sterile or post menopausal, to use reliable methods of birth control for the duration of the study and for 30 days after the last dose of study medication.
- •Patient must have signed informed consent prior to registration on study.
- •Resolution of all acute toxic effects of any prior local treatment to Common Terminology Criteria for Adverse Events (CTCEA) Grade 1 or
- •At least one tumor lesion can be accurately measured in at least one dimension according to RECIST. The lesion has not been previously treated with local therapy (such as surgery, radiation therapy, RFA, PEI, or cryoablation) unless it has shown progression in the interim.
排除标准
- •Patients unable to swallow oral medications
- •Prior embolization, systemic or radiation therapy for HCC (liver)
- •Tumor burden in the liver exceeding 70%.
- •Complete occlusion of the entire portal venous system
- •Ascites refractory to diuretic therapy (minimal or trace on imaging is acceptable)
- •Previous or concurrent cancer that is distinct in primary site or histology from HCC, except cervical carcinoma in situ, treated basal cell carcinoma, superficial bladder tumors (Ta, Tis, and T1). Any cancer curatively treated > 3 years prior is permitted.
- •Patients with clinically significant gastrointestinal bleeding within 30 days prior to study entry
- •History of bleeding within the past 4 weeks (unless deemed by PI as clinically insignificant, for ex., a brief episode of epistaxis)
- •Any contraindication to doxorubicin administration
- •Evidence of severe or uncontrolled systemic diseases,
- •Congestive cardiac failure > New York Heart Association (NYHA) class 2, myocardial ischemia within 6 months, active coronary artery disease, cardiac arrhythmias requiring anti-arrhythmic therapy other than beta blockers or digoxin, unstable angina, or laboratory finding that in the view of the investigator makes it undesirable for the patient to participate in the trial
- •Any prior history of hypertensive crisis or hypertensive encephalopathy
- •History of stroke or transient ischemic attack within 6 months prior to study enrollment
- •Inadequately controlled hypertension (defined as systolic blood pressure of 150/100 mmHg on antihypertensive medications) (patients with treated hypertension are eligible)
- •Significant vascular disease (e.g., aortic aneurysm, aortic dissection, peripheral vascular disease)
- •History of organ allograft
- •Presence of grade > 2 hepatic encephalopathy (see Appendix D)
- •Current, recent (within 4 weeks of the first infusion of this study), or planned participation in an additional experimental drug
- •Evidence of bleeding diathesis or coagulopathy or on warfarin. Note: If a patient has been on coumadin for a period of 1 month and has been stable, they may be accepted into the protocol.
- •Presence of clinically evident central nervous system or brain metastases
- •Major surgical procedure, open biopsy, or significant traumatic injury within 28 days prior to Day 1, anticipation of need for major surgical procedure during the course of the study
- •Vascular anatomy that precludes catheter placement or injection of LC Bead microspheres
- •Presence of collateral vessel pathways potentially endangering normal territories during embolization
- •Pregnant (positive pregnancy test) or lactating
- •Inability to comply with study and/or follow-up procedures
- •Life expectancy of less than 12 weeks
- •Child B8, B9 and C
- •Patients with concomitant HIV infection or AIDS-related or serious acute or chronic illness
- •Presence of porto-systemic shunt
- •Severe atheromatosis
- •Substance abuse, medical, psychological or social conditions that may interfere with the patient's participation in the study or evaluation of study results
- •Active clinically serious infections (>grade 2)
- •Patients receiving therapy for hepatitis A, B, or C.
- •Patients with obvious and/or symptomatic extrahepatic disease. Findings of uncertain significance, such as lung lesions less than 10 mm in diameter or enlarged periportal lymph nodes will not exclude patients, however, findings highly suspicious for metastatic HCC will exclude patients from this study.
- •Any contraindication for an arterial procedure such as impaired clotting tests (platelet count < 50.000/mm3 or prothrombin activity < 50 percent)
- •Any contraindication for systemic chemotherapy administration (serum bilirubin > 3mg/dL, leukocyte count < 3.000 cells/mm3)
- •Any contraindication for sorafenib administration
研究组 & 干预措施
sorafenib and drug eluting beads
Experimental
single arm
干预措施: sorafenib (Drug)
sorafenib and drug eluting beads
Experimental
single arm
干预措施: LC Bead-TACE (Procedure)
结局指标
主要结局
Safety Will be Assessed by Grading Toxicities Reported at Intervals Throughout the Study. Higher Grade Toxicities Will be Assessed for Their Degree of Relatedness to the Study Treatment.
时间窗: 2 years (Cycles 2-5+)
Treatment toxicities assessed by CTCAE v3.0 were stratified by cycle - patients on Cycle 1, and patients on Cycles 2-5 or more.
次要结局
- Efficacy Assessed by Response Evaluation Criteria in Solid Tumors (RECIST) to Determine Response and Disease Control Rate(6 months)
- Efficacy Assessed by European Association for the Study of the Liver (EASL) Criteria to Determine Response and Disease Control Rate(6 months)
- Efficacy - Median TTP After Combination Treatment With Sorafenib and TACE(3 years)
- Efficacy - Overall Survival (OS) After Combination Treatment With Sorafenib and TACE(3 years)
- Efficacy - Factors Associated With Overall Survival (OS) After Combination Treatment With Sorafenib and TACE(3 years)
研究者
研究点 (1)
Loading locations...
相似试验
撤回
2 期
Study of Sorafenib, Gemcitabine, and Cisplatin in Advanced Hepatocellular Carcinoma (HCC)Hepatocellular CarcinomaNCT00808145Lahey Clinic
已完成
2 期
Urea Cream Treatment Sorafenib-Associated HSFR in HCCHepatocellular CarcinomaNCT01934829Chinese Anti-Cancer Association871
进行中（未招募）
2 期
Sorafenib Plus Doxorubicin in Patients With Advanced Hepatocellular Carcinoma With Disease Progression on SorafenibHepatocellular CarcinomaNCT01840592Memorial Sloan Kettering Cancer Center30
已完成
2 期
Combination of Regorafenib and Nivolumab in Unresectable Hepatocellular CarcinomaCarcinoma, HepatocellularHepatomaNCT04310709Asan Medical Center42
已完成
2 期
Sorafenib Plus Tegafur/Uracil (UFUR®) for Hepatocellular Carcinoma (HCC)Hepatocellular CarcinomaNCT00464919National Taiwan University Hospital50